Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488]

Richard J Sylvester¹, Oscar Rodríguez², Virginia Hernández³, Diana Turturica⁴, Lenka Bauerová⁵, Harman Max Bruins⁶, Johannes Bründl⁷, Theo H van der Kwast⁸, Antonin Brisuda⁹, José Rubio-Briones¹⁰, Maximilian Seles¹¹, Anouk E Hentschel¹², Venkata R M Kusuma¹³, Nicolai Huebner¹⁴, Juliette Cotte¹⁵, Laura S Mertens¹⁶, Dimitrios Volanis¹⁷, Olivier Cussenot¹⁷, Jose D Subiela Henríquez², Enrique de la Peña¹⁸, Francesca Pisano¹⁹, Michael Pešl²⁰, Antoine G van der Heijden²¹, Sonja Herdegen⁷, Alexandre R Zlotta²², Jaromir Hacek²³, Ana Calatrava²⁴, Sebastian Mannweiler²⁵, Judith Bosschieter²⁶, David Ashabere¹³, Andrea Haitel²⁷, Jean-François Côté²⁸, Soha El Sheikh²⁹, Luca Lunelli³⁰, Ferran Algaba³¹, Isabel Alemany³², Francesco Soria⁴, Willemien Runneboom³³, Johannes Breyer⁷, Jakko A Nieuwenhuijzen²⁶, Carlos Llorente¹⁸, Luca Molinaro³⁴, Christina A Hulsbergen-van de Kaa³³, Matthias Evert³⁵, Lambertus A L M Kiemeney³⁶, James N'Dow³⁷, Karin Plass³⁷, Otakar Čapoun³⁸, Viktor Soukup³⁸, Jose L Dominguez-Escrig³⁹, Daniel Cohen⁴⁰, Joan Palou⁴¹, Paolo Gontero⁴², Maximilian Burger⁴³, Richard Zigeuner⁴⁴, Amir Hugh Mostafid⁴⁵, Shahrokh F Shariat⁴⁶, Morgan Rouprêt⁴⁷, Eva M Compérat⁴⁸, Marko Babjuk⁴⁶, Bas W G van Rhijn⁴⁹

Affiliations

¹ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Electronic address: richard.sylvester@skynet.be.
² Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
⁴ Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
⁵ Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
⁶ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁷ Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
⁸ Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
⁹ Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
¹⁰ Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
¹¹ Department of Urology, Medical University of Graz, Graz, Austria.
¹² Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
¹³ Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
¹⁴ Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
¹⁵ Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.
¹⁶ Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
¹⁷ Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
¹⁸ Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
¹⁹ Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
²⁰ Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
²¹ Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
²² Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
²³ Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
²⁴ Department of Pathology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
²⁵ Department of Pathology, Medical University of Graz, Graz, Austria.
²⁶ Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
²⁷ Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
²⁸ Department of Pathology, Pitié Salpétrière Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France.
²⁹ Department of Pathology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
³⁰ Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
³¹ Department of Pathology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
³² Department of Pathology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
³³ Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
³⁴ Department of Pathology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
³⁵ Department of Pathology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
³⁶ Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
³⁷ European Association of Urology Guidelines Office, Arnhem, The Netherlands.
³⁸ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
³⁹ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
⁴⁰ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
⁴¹ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁴² European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
⁴³ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
⁴⁴ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria.
⁴⁵ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
⁴⁶ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
⁴⁷ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.
⁴⁸ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
⁴⁹ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.

PMID: 36841687
DOI: 10.1016/j.eururo.2023.02.007

Published Erratum

Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488]

Richard J Sylvester et al. Eur Urol. 2023 May.

. 2023 May;83(5):e140-e141.

doi: 10.1016/j.eururo.2023.02.007. Epub 2023 Feb 24.

Authors

Affiliations

¹ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Electronic address: richard.sylvester@skynet.be.
² Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
⁴ Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
⁵ Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
⁶ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁷ Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
⁸ Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
⁹ Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
¹⁰ Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
¹¹ Department of Urology, Medical University of Graz, Graz, Austria.
¹² Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
¹³ Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
¹⁴ Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
¹⁵ Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.
¹⁶ Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
¹⁷ Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
¹⁸ Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
¹⁹ Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
²⁰ Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
²¹ Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
²² Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
²³ Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
²⁴ Department of Pathology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
²⁵ Department of Pathology, Medical University of Graz, Graz, Austria.
²⁶ Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
²⁷ Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
²⁸ Department of Pathology, Pitié Salpétrière Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France.
²⁹ Department of Pathology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
³⁰ Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
³¹ Department of Pathology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
³² Department of Pathology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
³³ Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
³⁴ Department of Pathology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
³⁵ Department of Pathology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
³⁶ Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
³⁷ European Association of Urology Guidelines Office, Arnhem, The Netherlands.
³⁸ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
³⁹ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
⁴⁰ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
⁴¹ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁴² European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
⁴³ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
⁴⁴ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria.
⁴⁵ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
⁴⁶ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
⁴⁷ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.
⁴⁸ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
⁴⁹ European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.

PMID: 36841687
DOI: 10.1016/j.eururo.2023.02.007

No abstract available

PubMed Disclaimer

Erratum for

European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, Bründl J, van der Kwast TH, Brisuda A, Rubio-Briones J, Seles M, Hentschel AE, Kusuma VRM, Huebner N, Cotte J, Mertens LS, Volanis D, Cussenot O, Subiela Henríquez JD, de la Peña E, Pisano F, Pešl M, van der Heijden AG, Herdegen S, Zlotta AR, Hacek J, Calatrava A, Mannweiler S, Bosschieter J, Ashabere D, Haitel A, Côté JF, El Sheikh S, Lunelli L, Algaba F, Alemany I, Soria F, Runneboom W, Breyer J, Nieuwenhuijzen JA, Llorente C, Molinaro L, Hulsbergen-van de Kaa CA, Evert M, Kiemeney LALM, N'Dow J, Plass K, Čapoun O, Soukup V, Dominguez-Escrig JL, Cohen D, Palou J, Gontero P, Burger M, Zigeuner R, Mostafid AH, Shariat SF, Rouprêt M, Compérat EM, Babjuk M, van Rhijn BWG. Sylvester RJ, et al. Eur Urol. 2021 Apr;79(4):480-488. doi: 10.1016/j.eururo.2020.12.033. Epub 2021 Jan 6. Eur Urol. 2021. PMID: 33419683

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488]

Affiliations

Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources